CORNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends September 30
Cencora, Inc.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$340.00−0.92 (-0.27%)
Close on Oct 19, 2026
- Market cap
- $65.94B
- P/E (TTM)
- 25.2
- Dividend yield
- 0.65%
Cencora, Inc. revenue by segment
By business segment
| Revenue | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S. Healthcare Solutions | $300.10B | $296.58B | $294.64B | $290.98B | $282.39B | $278.24B | $272.71B | $265.34B | $255.60B | $248.31B | $243.71B | $234.76B | 90.2% | +6.3% |
| International Healthcare Solutions | $32.33B | $31.90B | $31.03B | $30.37B | $28.29B | $28.09B | $28.52B | $28.63B | $28.24B | $28.24B | $27.88B | $27.42B | 9.7% | +14.3% |
| Operating income | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S. Healthcare Solutions | $3.90B | $3.77B | $3.72B | $3.57B | $3.16B | $3.03B | $2.92B | $2.93B | $2.87B | $2.81B | $2.72B | $2.60B | +23.5% |
| International Healthcare Solutions | $675.03M | $646.45M | $625.25M | $648.27M | $610.73M | $652.84M | $690.96M | $713.38M | $727.86M | $735.60M | $718.88M | $692.56M | +10.5% |
By product or service
By region
From the segment and revenue-disaggregation notes of Cencora's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.